{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:11:40Z","timestamp":1782846700506,"version":"3.54.5"},"reference-count":24,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Clin Cancer Inform"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Categorizing patients with cancer by their disease stage can be an important tool when conducting administrative claims-based studies. As claims databases frequently do not capture this information, algorithms are increasingly used to define disease stage. To our knowledge, to date, no study has used an algorithm to categorize patients with bladder cancer (BC) by disease stage (non\u2013muscle-invasive BC [NMIBC], muscle-invasive BC [MIBC], or locally advanced\/metastatic urothelial carcinoma [la\/mUC]) in a US-based health care claims database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>A claims-based algorithm was developed to categorize patients by disease stage on the basis of the administrative claims portion of the SEER-Medicare linked data. The algorithm was validated against a reference SEER registry, and the algorithm's parameters were iteratively modified to improve its performance. Patients were included if they had an initial diagnosis of BC between January 2016 and December 2017 recorded in SEER registry data. Medicare claims data were available for these patients until December 31, 2019. The algorithm was evaluated by assessing percentage agreement, Cohen's kappa (\u03ba), specificity, positive predictive value (PPV), and negative predictive value (NPV) against the SEER categorization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>A total of 15,484 patients with SEER-confirmed BC were included: 10,991 (71.0%) with NMIBC, 3,645 (23.5%) with MIBC, and 848 (5.5%) with la\/mUC. After multiple rounds of algorithm optimization, the final algorithm had an agreement of 82.5% with SEER, with a \u03ba of 0.58, a PPV of 87.0% for NMIBC, and 76.8% for MIBC and a high NPV for la\/mUC of 98.0%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>This claims-based algorithm could be a useful approach for researchers conducting claims-based studies categorizing patients with BC at diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/cci.24.00073","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T16:00:06Z","timestamp":1726761606000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Development and Optimization of a Bladder Cancer Algorithm Using SEER-Medicare Claims Data"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2847-5062","authenticated-orcid":true,"given":"John L.","family":"Gore","sequence":"first","affiliation":[{"name":"University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9260-2303","authenticated-orcid":true,"given":"Phoebe","family":"Wright","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Shih","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2986-6647","authenticated-orcid":true,"given":"Nancy N.","family":"Chang","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Noshad","sequence":"additional","affiliation":[{"name":"Genesis Research Group, Hoboken, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel G.","family":"Rey","sequence":"additional","affiliation":[{"name":"Genesis Research Group, Hoboken, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Wang","sequence":"additional","affiliation":[{"name":"Genesis Research Group, Hoboken, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_6_2_2","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala K","year":"2020","unstructured":"Saginala K, Barsouk A, Aluru JS, et al: Epidemiology of bladder cancer. Med Sci (Basel) 8:15, 2020","journal-title":"Med Sci (Basel)"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.20285"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29100599"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11590"},{"key":"e_1_3_6_7_2","volume-title":"TNM Classification","author":"Rosen RD","year":"2024","unstructured":"Rosen RD, Sapra A: TNM Classification. Treasure Island, FL, StatPearls, 2024. Disclosure: Amit Sapra declares no relevant financial relationships with ineligible companies, StatPearls Publishing Copyright \u00a9 2024, StatPearls Publishing LLC"},{"key":"e_1_3_6_8_2","volume-title":"An Interactive Website for SEER Cancer Statistics. Surveillance Research Program","author":"SEER*Explorer","unstructured":"SEER*Explorer: An Interactive Website for SEER Cancer Statistics. Surveillance Research Program. National Cancer Institute. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.012"},{"key":"e_1_3_6_10_2","article-title":"Classifying stage IV lung cancer from health care claims: A comparison of multiple analytic approaches","author":"Brooks GA","unstructured":"Brooks GA, Bergquist SL, Landrum MB, et al: Classifying stage IV lung cancer from health care claims: A comparison of multiple analytic approaches. JCO Clin Cancer Inform 10.1200\/CCI.18.00156","journal-title":"JCO Clin Cancer Inform"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2019.05.006"},{"key":"e_1_3_6_12_2","first-page":"25","article-title":"Classifying lung cancer severity with ensemble machine learning in health care claims data","volume":"68","author":"Bergquist SL","year":"2017","unstructured":"Bergquist SL, Brooks GA, Keating NL, et al: Classifying lung cancer severity with ensemble machine learning in health care claims data. Proc Mach Learn Res 68:25-38, 2017","journal-title":"Proc Mach Learn Res"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-5573-7-1"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-0677"},{"key":"e_1_3_6_15_2","unstructured":"FDA: FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer"},{"key":"e_1_3_6_16_2","unstructured":"FDA: FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle-invasive-bladder-cancer"},{"key":"e_1_3_6_17_2","unstructured":"FDA: FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-combination-cisplatin-and-gemcitabine-unresectable-or-metastatic-urothelial"},{"key":"e_1_3_6_18_2","unstructured":"National Cancer Institute: SEER-medicare: Brief description of the SEER-medicare database. https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/overview\/"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.2307\/2529310"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5537"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5601"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57050503"},{"key":"e_1_3_6_23_2","first-page":"135","article-title":"Bladder cancer in the elderly: Clinical outcomes, basic mechanisms, and future research direction","volume":"6","author":"Taylor JA","year":"2009","unstructured":"Taylor JA III, Kuchel GA: Bladder cancer in the elderly: Clinical outcomes, basic mechanisms, and future research direction. Nat Clin Pract Urol 6:135-144, 2009","journal-title":"Nat Clin Pract Urol"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_158974"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.01.007"}],"container-title":["JCO Clinical Cancer Informatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/CCI.24.00073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:32:35Z","timestamp":1782844355000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/CCI.24.00073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1200\/CCI.24.00073"],"URL":"https:\/\/doi.org\/10.1200\/cci.24.00073","relation":{},"ISSN":["2473-4276"],"issn-type":[{"value":"2473-4276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"2024-03-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2400073"}}